We advised the initial purchasers on the offering

Davis Polk acted as special product counsel to the initial purchasers in a Rule 144A offering by CRISPR Therapeutics AG of $600 million aggregate principal amount of its convertible senior notes due 2031, including $50 million aggregate principal amount of convertible notes pursuant to the full exercise of the initial purchasers’ option to purchase additional convertible notes.

CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases.

The Davis Polk equity derivatives team included partner Caitlin L. Wood, counsel Katharine O’Banion and associate Jessica Carter. The tax team included partner Aliza Slansky and associates Yueyu Yang and Summer Elbardissy. All members of the Davis Polk team are based in the New York office.

Copy link to share post